Roger G Ptak

Summary

Publications

  1. pmc Cataloguing the HIV type 1 human protein interaction network
    Roger G Ptak
    Department of Infectious Disease Research, Southern Research Institute, 431 Aviation Way, Frederick, MD 21701, USA
    AIDS Res Hum Retroviruses 24:1497-502. 2008
  2. pmc Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef
    Roger G Ptak
    Department of Infectious Disease Research, Southern Research Institute, Frederick, Maryland 21701, USA
    Antimicrob Agents Chemother 54:1512-9. 2010
  3. pmc Human immunodeficiency virus type 1, human protein interaction database at NCBI
    William Fu
    Southern Research Institute, Frederick, MD 21701, USA
    Nucleic Acids Res 37:D417-22. 2009
  4. pmc Suboptimal inhibition of protease activity in human immunodeficiency virus type 1: effects on virion morphogenesis and RNA maturation
    Michael D Moore
    HIV Drug Resistance Program, National Cancer Institute at Frederick, P O Box B, Building 535, Room 336, Frederick, Maryland 21702, USA
    Virology 379:152-60. 2008
  5. pmc Mechanisms of human immunodeficiency virus type 2 RNA packaging: efficient trans packaging and selection of RNA copackaging partners
    Na Ni
    HIV Drug Resistance Program, NCI Frederick, P O Box B, Building 535, Room 336, Frederick, MD 21702, USA
    J Virol 85:7603-12. 2011
  6. pmc Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent
    Roger G Ptak
    Southern Research Institute, Frederick, Maryland 21701, USA
    Antimicrob Agents Chemother 52:1302-17. 2008
  7. pmc Cross-reactive HIV-1-neutralizing activity of serum IgG from a rabbit immunized with gp41 fused to IgG1 Fc: possible role of the prolonged half-life of the immunogen
    Mei Yun Zhang
    Center for Cancer Research Nanobiology Program, CCR, NCI Frederick, NIH, Frederick, MD 21702, USA
    Vaccine 27:857-63. 2009
  8. ncbi request reprint Inhibition of HIV-1 replication by amphotericin B methyl ester: selection for resistant variants
    Abdul A Waheed
    Virus Cell Interaction Section, HIV Drug Resistance Program, NCI Frederick, National Institutes of Health, Frederick, Maryland 21702 1201, USA
    J Biol Chem 281:28699-711. 2006
  9. pmc Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides
    Carol Lackman-Smith
    Southern Research Institute, 431 Aviation Way, Frederick, Maryland 21701, USA
    Antimicrob Agents Chemother 52:1768-81. 2008
  10. pmc Dimer initiation signal of human immunodeficiency virus type 1: its role in partner selection during RNA copackaging and its effects on recombination
    Michael D Moore
    HIV Drug Resistance Program, NCI Frederick, P O Box B, Building 535, Room 336, Frederick, MD 21702, USA
    J Virol 81:4002-11. 2007

Collaborators

Detail Information

Publications11

  1. pmc Cataloguing the HIV type 1 human protein interaction network
    Roger G Ptak
    Department of Infectious Disease Research, Southern Research Institute, 431 Aviation Way, Frederick, MD 21701, USA
    AIDS Res Hum Retroviruses 24:1497-502. 2008
    ..This database represents a unique and continuously updated scientific resource for understanding HIV-1 replication and pathogenesis to assist in accelerating the development of effective therapeutic and vaccine interventions...
  2. pmc Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef
    Roger G Ptak
    Department of Infectious Disease Research, Southern Research Institute, Frederick, Maryland 21701, USA
    Antimicrob Agents Chemother 54:1512-9. 2010
    ..We conclude that TCN is a late-phase inhibitor of HIV-1 replication and that mutations in nef are necessary and sufficient for TCN resistance...
  3. pmc Human immunodeficiency virus type 1, human protein interaction database at NCBI
    William Fu
    Southern Research Institute, Frederick, MD 21701, USA
    Nucleic Acids Res 37:D417-22. 2009
    ..The database is also tightly linked to other databases through Entrez Gene, enabling users to search for an abundance of information related to HIV pathogenesis and replication...
  4. pmc Suboptimal inhibition of protease activity in human immunodeficiency virus type 1: effects on virion morphogenesis and RNA maturation
    Michael D Moore
    HIV Drug Resistance Program, National Cancer Institute at Frederick, P O Box B, Building 535, Room 336, Frederick, Maryland 21702, USA
    Virology 379:152-60. 2008
    ..Intriguingly, drug treatments caused only a slight decrease in overall thermodynamic stability of the viral RNA dimer, suggesting that the dimeric viral RNA was able to mature in the absence of correct core condensation...
  5. pmc Mechanisms of human immunodeficiency virus type 2 RNA packaging: efficient trans packaging and selection of RNA copackaging partners
    Na Ni
    HIV Drug Resistance Program, NCI Frederick, P O Box B, Building 535, Room 336, Frederick, MD 21702, USA
    J Virol 85:7603-12. 2011
    ..Together, these results revealed mechanisms of HIV-2 RNA packaging that are, contrary to previous studies, in many respects surprisingly similar to those of HIV-1...
  6. pmc Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent
    Roger G Ptak
    Southern Research Institute, Frederick, Maryland 21701, USA
    Antimicrob Agents Chemother 52:1302-17. 2008
    ..Thus, Debio-025 seems to interfere with the function of CypA during the progression/completion of HIV-1 reverse transcription...
  7. pmc Cross-reactive HIV-1-neutralizing activity of serum IgG from a rabbit immunized with gp41 fused to IgG1 Fc: possible role of the prolonged half-life of the immunogen
    Mei Yun Zhang
    Center for Cancer Research Nanobiology Program, CCR, NCI Frederick, NIH, Frederick, MD 21702, USA
    Vaccine 27:857-63. 2009
    ..Further research is needed to confirm and extend these results which may have implications for the development of vaccine immunogens with enhanced capability to elicit cross-reactive HIV-1-neutralizing antibodies...
  8. ncbi request reprint Inhibition of HIV-1 replication by amphotericin B methyl ester: selection for resistant variants
    Abdul A Waheed
    Virus Cell Interaction Section, HIV Drug Resistance Program, NCI Frederick, National Institutes of Health, Frederick, Maryland 21702 1201, USA
    J Biol Chem 281:28699-711. 2006
    ..Our data define the target and mechanism of action of AME and provide support for the concept that cholesterol-binding compounds should be pursued as antiretroviral drugs to disrupt HIV-1 replication...
  9. pmc Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides
    Carol Lackman-Smith
    Southern Research Institute, 431 Aviation Way, Frederick, Maryland 21701, USA
    Antimicrob Agents Chemother 52:1768-81. 2008
    ....
  10. pmc Dimer initiation signal of human immunodeficiency virus type 1: its role in partner selection during RNA copackaging and its effects on recombination
    Michael D Moore
    HIV Drug Resistance Program, NCI Frederick, P O Box B, Building 535, Room 336, Frederick, MD 21702, USA
    J Virol 81:4002-11. 2007
    ..These results also strongly support the hypothesis that HIV-1 RNA dimers are formed prior to encapsidation...
  11. ncbi request reprint HIV-1 regulatory proteins: targets for novel drug development
    Roger G Ptak
    Infectious Disease Research Department, Southern Research Institute, 431 Aviation Way, Frederick, Maryland 21701, USA
    Expert Opin Investig Drugs 11:1099-115. 2002
    ....